Seres Therapeutics stockholders approve 1-for-20 reverse stock split, 2025 Incentive Plan

Seres Therapeutics, Inc.

Reverse stock split at 1-for-20 ratio approved; effective April 21, 2025; trading on split-adjusted basis April 22 under symbol MCRB.
2025 Incentive Award Plan authorized 44,604,870 shares for future awards, amending and restating the 2015 Plan.
Three Class I directors elected: Dennis A. Ausiello, M.D.; Willard H. Dere, M.D.; Eric D. Shaff.
Advisory say-on-pay vote passed with 57.9M for vs 32.5M against.
Proposals to amend certificate to eliminate supermajority voting and clarify share authorization did not pass.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.